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Abstract
Objectives: In patients with suspected acute coronary syndrome (ACS), rapid triage is essential. The aim of this study was to
establish a tool for risk prediction of 30-day cardiac events (CE) on admission. 30-day cardiac events (CE) were defined as
early coronary revascularization, subsequent myocardial infarction, or cardiovascular death within 30 days.
Methods and Results: This single-centre, prospective cohort study included 377 consecutive patients presenting to the
emergency department with suspected ACS and for whom troponin T measurements were requested on clinical grounds.
Fifteen biomarkers were analyzed in the admission sample, and clinical parameters were assessed by the TIMI risk score for
unstable angina/Non-ST myocardial infarction and the GRACE risk score. Sixty-nine (18%) patients presented with and 308
(82%) without ST-elevations, respectively. Coronary angiography was performed in 165 (44%) patients with subsequent
percutaneous coronary intervention – accounting for the majority of CE – in 123 (33%) patients, respectively. Eleven out of
15 biomarkers were elevated in patients with CE compared to those without. High-sensitive troponin T (hs-cTnT) was the
best univariate biomarker to predict CE in Non-ST-elevation patients (AUC 0.80), but did not yield incremental information
above clinical TIMI risk score (AUC 0.80 vs 0.82, p = 0.69). Equivalence testing of AUCs of risk models and non-inferiority
testing demonstrated that the clinical TIMI risk score alone was non-inferior to its combination with hs-cTnT in predicting
CE.
Conclusions: In patients presenting without ST-elevations, identification of those prone to CE is best based on clinical
assessment based on TIMI risk score criteria and hs-cTnT.
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Introduction
Acute coronary syndromes (ACS) are a major cause of death
worldwide [1]. In emergency rooms, patients with chest pain and
symptoms suggestive of ACS account for a large part of medical
admissions [2]. However, a wide spectrum of clinical presentations
may be associated with cardiac ischemia. Hence, in these patients,
rapid identification, risk stratification, and appropriate selection
for early percutaneous coronary revascularization (PCI) or
coronary artery bypass grafting (CABG) are crucial for prognosis
[3–7].
Recently, testing for high-sensitive cardiac troponin (hs-cTnT)
has been shown to be even more sensitive compared to
conventional assays [8,9]. However, designed to improve the
detection of minimal myocardial injury and to minimize the
number of unidentified ACS patients, high-sensitive assays show
decreased specificity. Indeed, various cardiac and non-cardiac
conditions including tachyarrhythmias, hypertensive episodes,
congestive heart failure, pulmonary embolism, sepsis, and high-
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intensity training have been associated with a rise in hs-cTnT [10–
12]. Thus, despite the ability of clearly ruling-out the likelihood of
ACS in patients with chest pain, the increased number of
individuals testing positive for troponin has hampered decision
making in daily clinical practice. Particularly, the decision when to
perform coronary angiography in individuals without obvious ST-
segment elevations (Non-ST-elevation patients) remains challeng-
ing and calls for complementary rule-in parameters to identify
those at particular risk of impending cardiac events (CE).
Accordingly, for the purpose of this study, CE comprise not only
the conventional endpoints of subsequent myocardial infarction
and cardiovascular death, but, by operational definition, also the
need for coronary revascularization established by means of
coronary angiography.
Besides sensitive indicators of myocardial injury such as heart-
type fatty acid-binding protein (H-FABP) [13,14], markers of
coronary plaque activation and/or instability appear most
promising in such context. Several groups, including our own,
have recently suggested myeloid-related protein 8/14 (MRP 8/
14), a marker of phagocyte activation – highly expressed in
coronary thrombi – as a candidate marker for the early detection
of atherothrombosis and ACS [15–17]. Early indicators of
coronary plaque instability also include pregnancy-associated
plasma protein A (PAPP-A), a metalloproteinase exhibiting pro-
atherosclerotic effects, and myeloperoxidase (MPO), an oxidative
leukocyte enzyme, which has been shown to predict CE even in
patients who are negative for troponin T [18,19]. Yet, the
complexity of the molecular pathways in the chain of events
leading to ACS, as well as the heterogeneity in clinical
presentation, imply that a single-marker strategy is most likely
inferior to a multi-marker approach. Indeed, multi-marker testing
adds useful prognostic information to that of individual markers,
both for the prediction of early and long-term outcomes in patients
with suspected ACS [20–22]. However, the potential of different
novel cardiac biomarkers in comparison to and combined with
clinical assessment in predicting CE in individuals presenting with
symptoms suggestive of ACS has not been fully elucidated.
Thus, we investigated within a prospective single-center study,
initially designed to assess the diagnostic role of MRP 8/14 in
patients presenting with suspected ACS – Myeloid Related Protein
8/14 in the Evaluation of Acute Chest Pain in the Emergency
Department (MyRiAD study) – the predictive value of 15
biomarkers, stand-alone or in combination with established
clinical parameters, for CE within 30 days.
Methods
Study design and patient enrollment
This single-centre, prospective observational study included
patients presenting to the emergency room from July 2007 to April
2008 with symptoms suggestive of ACS and for whom conven-
tional troponin (c-cTnT) measurements were requested on clinical
grounds. Exclusion criteria were the onset of symptoms .
24 hours, clinical signs of infection, and refusal or inability of
the patient to give informed consent. Of 538 patients screened,
377 patients were included in the final analysis.
Assuming an event rate of 30% and an area under the curve
(AUC) of 0.8 for MRP 8/14 to predict CE (according to the initial
MyRiAD study hypothesis), a minimal number of 326 patients was
calculated in order to obtain a power of 80% and an alpha-level of
0.05. The study was carried out according to the principles of the
Declaration of Helsinki and approved by the institutional ethics
committee of the University Hospital Zurich. Written informed
consent was obtained from all patients.
Patient management
All patients underwent the regular emergency room assessments
including detailed clinical history taking, physical examination, 12-
lead electrocardiogram (ECG), and the pertinent blood analysis
routine (see below). Subsequent clinical management, in particular
as to additional examinations (i.e. coronary angiography) and
therapies, was based on current practice and left at the discretion
of the treating physicians. Routine markers including c-cTnT,
myoglobin, creatine kinase (CK), creatine kinase-myocardial band
(CK-MB), N-terminal pro-brain natriuretic peptide (NT-proBNP),
and D-dimers were available to the treating physicians. There
were no study-specific interventions. Details on screening,
enrollment, and patient management are summarized in the
study flow chart (figure 1).
Biomarker analysis
Blood samples were harvested in serum, heparin plasma, and
citrate plasma tubes and immediately processed by the Institute of
Clinical Chemistry. Subsequently, routine markers for the
assessment of myocardial infarction were directly assessed, and
the remaining samples deep-frozen and stored (-70uC) for later
analysis of specific biomarkers.
Routine markers included c-cTnT, myoglobin, CK, CK-MB,
and NT-proBNP, which were analyzed from heparin plasma
(maximal inter-assay variation 3.7%, 2.5%, 1.8%, 2.8%, and
4.4%, respectively; limit of detection of 10 ng/L, 21 mg/L, 7 U/L,
3.0 U/L, and 5.0 gg/L with a functional assay sensitivity of 10%).
D-dimers were determined from citrate plasma on a Roche
Modular Analytics System using commercial assays from Roche
Diagnostics (Rotkreuz, Switzerland).
Study specific blood analyses were limited to the sample
collected on admission and included MRP 8/14, H-FABP, high-
sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), MPO,
PAPP-A, insulin-like growth factor 1 (IGF-1), and fibrinogen.
Interleukin-6 and hs-CRP were determined from heparin plasma,
and IGF-1 from serum on an Immulite 2000 chemiluminescence
analyser using commercial assays from Siemens Healthcare
Diagnostics GmbH (Deerfield, USA; maximal inter-assay varia-
tion of 2.7%, 3.1%, and 4.5%, respectively; limit of detection of
1.5 gg/L, 0.3 mg/L, and 3.0 mg/L with a functional assay
sensitivity of 10%). Pregnancy-associated plasma protein A was
measured immunochemically by Time Resolved Amplified
Cryptate Emission (TRACE) from serum on a Kryptor analyzer
from Brahms AG (Hennigsdorf, Germany; maximal inter-assay
variation of 4.7%; limit of detection of 0.004 U/L with a
functional assay sensitivity of 10%). Fibrinogen was determined
on a CA7000 analyzer from Siemens Healthcare Diagnostics
GmbH using commercial assays (maximal inter-assay variation of
4.8%). Myeloid-related protein 8/14 was determined from serum
using assays from Buehlmann Laboratories (Schoenenbuch,
Switzerland; limit of detection of 0.4 mg/mL; cut-off value of
4.7 mg/mL). Heart-type fatty acid-binding protein was measured
from serum using assays from Hycult biotechnology (Uden, The
Netherlands; limit of detection of 0.1 gg/mL, cut-off value of 5
gg/mL). Samples were tested in double determination, if the two
values differed by more than 10%, the sample was repeated, unless
absorbance was ,0.1 or both concentration values were clearly
within the normal range. Concentrations of hs-cTnT were
analyzed from serum with the Elecsys assay from Roche
Diagnostics (Mannheim, Germany; limit of detection 5 pg/mL,
cut-off value of 13 pg/mL). Myeloperoxidase was measured from
heparin plasma using assays from Immundiagnostik (Bensheim,
Germany; limit of detection of 1.6 ng/mL).
Clinical Criteria and Biomarkers in ACS
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Patient assessment and outcome measures
Assessment of patients with suspected ACS was primarily based
on ECG, notably the presence of new or presumed new ST-
elevation $0.2 mV in $2 contiguous leads, as an indicator of
likely acute total coronary artery occlusion necessitating immedi-
ate invasive reperfusion strategies (ST-elevation patients). In Non-
ST-elevation patients, pretest probability of ACS was assessed by
the TIMI risk score for unstable angina/Non-ST myocardial
infarction, which allows stratification into those at low, interme-
diate, and high risk of adverse CE. The original TIMI risk score
includes 7 predictor variables: 1) age $65 years, 2) $ 3 risk factors
for coronary artery disease, 3) documented significant coronary
artery disease on previous coronary angiography (i.e. coronary
artery stenosis $ 50%), 4) persistent ST depression of $ 0.05 mV,
5) $ 2 episodes of angina in the last 24 hours, 6) aspirin use within
the last 7 days prior to admission, and 7) elevated cardiac
biomarkers, with each adding 1 point (score 0-7 points) [23]. If
aspirin was administered by the emergency physician or
afterwards, it was not included in the clinical TIMI risk score
calculation. For the particular purpose of this study, namely to
assess the incremental predictive value of singular specific cardiac
biomarkers over established clinical risk parameters, the original
calculation of the TIMI risk score was modified by including all
predictor variables except the one ‘elevated cardiac biomarkers’;
hence, the TIMI risk score utilized in the present study is named
the ‘‘clinical TIMI risk score’’.
To allow comparison between different risk scoring systems in
ACS, in all patients, the Global Registry of Acute Coronary Events
(GRACE) score was calculated. This score includes age, heart rate,
systolic blood pressure, creatinine, Killip Class, cardiac arrest at
admission, ST-segment deviation, and elevated cardiac enzymes
[24]. According to the ‘‘clinical TIMI risk score’’, the original
calculation of the GRACE risk score was modified by including all
predictor variables except the one ‘elevated cardiac enzymes’;
hence, the GRACE risk score utilized in the present study is
named the ‘‘clinical GRACE risk score’’.
In analogy to the endpoints in the TIMI risk score validation
study, the main outcome measure was CE, for the purpose of this
study specifically and operationally defined as a composite of early
coronary revascularization by PCI or CABG, cardiovascular
mortality, and subsequent myocardial infarction requiring revas-
cularization within 30 days [23,25].
Data collection and statistical analysis
All data and imaging records including coronary angiographies
and interventions were reviewed and entered into a dedicated,
individually designed, and web-based database. Before the final
Figure 1. Study flow chart of the prospective, observational MyRiAD study. Abbreviations: ER, emergency room; CA, coronary angiography;
CAD, coronary artery disease; CE, cardiac events (composite of early coronary revascularization by percutaneous coronary intervention [PCI] or
coronary artery bypass grafting [CABG], subsequent myocardial infarction or cardiovascular death); c-cTnT, conventional cardiac troponin T; CK,
creatine kinase; CK-MB, creatine kinase-myocardial band.
doi:10.1371/journal.pone.0098626.g001
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analysis, data were monitored and cross-validated according to
clinical trial center standard operating procedures.
Continuous variables are presented as medians and interquartile
range as they were not normally distributed as assessed by the
Shapiro-Wilk W test. Categorical variables are given as frequen-
cies and percentages. Continuous variables were tested for
differences with the Wilcoxon signed-rank test or the Mann-
Whitney U test as appropriate. The independence of two
categorical variables was tested by the Pearson’s Chi-square test.
Receiver-operator-characteristic (ROC) curves were constructed
to assess AUCs, sensitivity, and specificity of cardiac biomarkers in
predicting CE at 30 days.
For multivariate analysis we used decision tree technique
allowing multi-level splits based upon adjusted significance testing
(Bonferroni testing). The goal was to create a model that predicted
the value of the target variable ‘‘CE within 30 days’’ based on
several input variables (clinical parameters and biomarkers). Each
interior node corresponds to one of the input variables, each leaf
represents a value of the target variable given the values of the
input variables represented by the path from the root to the leaf.
Binary logistic regression with and without bootstrapping as well
as standard generalized linear models for the logistic regression
models were used to test predictors of the outcome variable and to
establish two risk prediction models (model I: clinical TIMI risk
score, and gender; model II: clinical TIMI risk score, gender, and
hs-TnT). For comparisons between models, empirical equivalence
tests of the AUCs, non-inferiority tests, as well as integrated
discrimination improvement (IDI) were performed, and the
performance of the two models illustrated as predictiveness curves.
Results
Baseline characteristics
Baseline characteristics of 377 patients stratified according to
the occurrence of CE within 30 days are summarized in table 1.
Urgent coronary angiography was performed in 165 (44%)
patients with subsequent PCI in 123 (33%) patients, and CABG
in 5 (1%) patients, respectively. From the 377 patients presenting
with suspected ACS, 132 (35%) were finally diagnosed with
coronary artery disease including 66 patients with acute STEMI,
and 66 patients with acute NSTEMI/UA, respectively. Median
time of symptom duration was 253 [148–496] minutes. Final
diagnoses of the patients are summarized in table 2.
In 6 patients, heparin was administered before the first blood
analysis. In 12 patients, no information about heparin adminis-
tration was available. The remaining 359 were treated with
heparin at the emergency room or during revascularization, or
received no heparin at all due to the clinical course.
Cardiac events (CE) in ST-elevation and Non-ST-elevation
patients
Of all patients, 69 (18%) presented with and 308 (82%) without
ST-elevations. Cardiac events within 30 days were observed in 131
(35%) and an uneventful course was noted in the remaining 246
(65%) patients. In ST-elevation patients, 66 (96%) underwent
coronary revascularization, 64 (93%) by PCI, and 2 (3%) by
CABG. One patient (1%) died without intervention and another 2
(2%) patients presenting with ST-elevations were diagnosed as
having Takotsubo cardiomyopathy with essentially normal coro-
naries and an uneventful 30-day course. In Non-ST-elevation
patients, 66 were diagnosed with coronary artery disease. CE
included revascularization in 62 (20%) patients with PCI in 59
(19%) and CABG in 3 (1%), cardiovascular death in 2 (1%), and
subsequent acute myocardial infarction in 1 (0.3%) patient,
respectively.
Biomarkers in patients with and without cardiac events
(CE) within 30 days
Levels of biomarkers in patients presenting with and without CE
are summarized in table 3. Patients with CE showed significantly
elevated levels of 11 out of 15 biomarkers compared to those
without, including all markers of myocardial ischemia/necrosis
(p,0.001 for CK, CK-MB, H-FABP, myoglobin, c-cTnT, and hs-
cTnT), 3 out of 4 inflammatory markers (p,0.03 for hs-CRP,
MPO, and MRP 8/14), and PAPP-A, a marker of atherosclerosis
(p,0.0001), as well as NT-proBNP (p = 0.04). No differences in
serum levels between patients with and without CE were observed
for IL-6, IGF-1, D-dimer, and fibrinogen, respectively.
Single biomarkers for the prediction of cardiac events
(CE) within 30 days in the total cohort of patients and in
Non-ST-elevation patients
Results from univariate analysis of biomarkers for the prediction
of CE within 30 days are summarized in table 4. In the total
cohort of patients presenting with suspected ACS, hs-cTnT was
the best single biomarker for the prediction of CE within 30 days
(AUC=0.83, sensitivity = 76%, and negative predictive value
[NPV]= 86% at a cut-off level of 16.2 pg/mL). Best specificity
(92%) resulting in the highest positive predictive value
(PPV=75%) at a cut-off level of 0.02 mg/L was noted for c-
cTnT, which overall was less predictive (AUC=0.69) than hs-
cTnT. Similarly, the predictive value of MRP 8/14 (AUC=0.65)
for CE within 30 days in patients with suspected ACS was inferior
to hs-cTnT.
In Non-ST-elevation patients, univariate analysis again revealed
hs-cTnT as the biomarker with the best performance in predicting
CE within 30 days (AUC=0.80, sensitivity = 86%, and
NPV=84% at a cut-off level 9.26 pg/mL). As for the total
cohort, specificity for detecting CE within 30 days by a single
marker in Non-ST-elevation patients was highest for c-cTnT, with
a specificity of 93% and a PPV of 55% at a cut-off level of
0.02 mg/L. Altogether, predictive values of single biomarkers for
CE within 30 days decreased in Non-ST-elevation compared to
the total population of patients with suspected ACS. This was
evidenced by smaller AUCs for all biomarkers except for NT-
proBNP, fibrinogen, D-dimer, and IGF-1, which showed an
increase in AUC.
Univariate decision tree analysis (CRT) in Non-ST-elevation
patients confirmed hs-cTnT as the best biomarker for the
prediction of CE within 30 days (classification = 84.7%), however,
with only minor incremental value over c-cTnT (classifica-
tion= 82.5%), and only if continuous values instead of the
manufacturer’s pre-defined cut-off level (13 pg/ml) were utilized.
The CE-rate increased highly significantly (p,0.001) with hs-
cTnT (hs-cTnT,9: 5.8%; 9#hs-cTNT,28: 22.6%; hs-cTNT$
28: 55.7%).
Clinical TIMI risk score for the prediction of cardiac events
(CE) in Non-ST-elevation patients
At presentation, in Non-ST-elevation patients, 66 (21%)
patients had a clinical TIMI risk score of 0, 69 (22%) patients of
1, 73 (24%) patients of 2, 60 (20%) patients of 3, 29 (9%) patients
of 4, 10 (3%) patients of 5, and 1 (0.3%) patient of 6, respectively.
The observed CE rate at 30 days was 100% (1/1) in patients with
a score of 6, 50% (5/10) in patients with a score of 5, 69% (20/29)
in patients with a score of 4, 35% (21/60) in patients with a score
Clinical Criteria and Biomarkers in ACS
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of 3, 14% (10/73) in patients with a score of 2, 9% (6/69) in those
with a score of 1, and 2% (1/66) in those with 0 points,
respectively. Hs-cTnT was not better than the clinical TIMI risk
score in predicting CE within 30 days, as substantiated both by
univariate ROC and decision tree analysis [AUC=0.80 (standard
error 0.03, 95% CI 0.74–0.86; p,0.001), vs. AUC=0.82
(standard error 0.03, 95% CI 0.76–0.87; p,0.001); p = 0.69].
Clinical GRACE risk score for the prediction of cardiac
events (CE) in Non-ST-elevation patients
At presentation, in Non-ST-elevation patients, the clinical
GRACE risk score was 92 (70–120). The observed CE rate at 30
days was 15% in patients with a score #100, and 29% in those
with a score .100, respectively (p = 0.003). The AUC was 0.62
(95% CI 0.54–0.69) for the clinical GRACE score in predicting
CE within 30 days.
Combination of the clinical TIMI risk score and
biomarkers for individual risk prediction and decision
making in Non-ST-elevation patients
For the clinical TIMI risk score, the AUC was 0.82 (95% CI
0.76–0.87) alone and 0.86 (95% CI 0.82–0.91) when combined
with hs-cTnT (p,0.001). The clinical TIMI risk score alone as
well as hs-cTnT (AUC=0.80, 95% CI 0.74–0.86) alone are not
inferior at the 5% significance level to the combination of the
clinical TIMI risk score with hs-cTnT.
Most remarkably, performance of single biomarkers – notably
of hs-cTnT, MPO, MRP 8/14, and c-cTnT – in predicting CE
within 30 days, depended on the clinical pretest probability of
ACS. Figure 2 illustrates ROC curves of hs-cTnT, MPO, MRP 8/
14, and c-cTnT for the prediction of CE within 30 days in patients
with low, intermediate, and high clinical TIMI risk scores,
respectively. In patients with low (#2) and intermediate ( = 3)
Table 1. Baseline characteristics.
Characteristics All patients Patients with cardiac events Patients free from cardiac events P value
(n=377) (n =131) (n =246)
Demographics
Age, years 60 [51–71] 62 [53–72] 59 [48–71] 0.10
Male gender, n (%) 275 (73) 111 (85) 164 (67) ,0.001
Risk factors
Family history of CAD, n (%) 105 (28) 40 (31) 65 (26) 0.26
Hypercholesterolemia, n (%) 173 (46) 70 (53) 103 (42) 0.03
Diabetes, n (%) 63 (18) 26 (20) 37 (15) 0.23
Hypertension, n (%) 214 (57) 89 (68) 125 (51) 0.001
Current smoker, n (%) 110 (29) 42 (32) 68 (28) 0.007
Previous history
Previous MI, n (%) 78 (21) 26 (20) 52 (21) 0.77
Previous CABG, n (%) 28 (7) 10 (8) 18 (7) 0.91
Previous PCI, n (%) 82 (22) 26 (20) 56 (23) 0.51
PVD, n (%) 26 (10) 16 (12) 20 (8) 0.20
CVD, n (%) 31 (8) 11 (8) 20 (8) 0.93
Previous medication
Aspirin, n (%) 147 (39) 51 (39) 96 (39) 0.99
Clopidogrel, n (%) 36 (10) 12 (8) 24 (10) 0.12
ACE-inhibitor, n (%) 83 (22) 20 (15) 63 (26) 0.02
Beta-blocker, n (%) 149 (40) 44 (34) 105 (43) 0.09
CCB, n (%) 52 (14) 22 (17) 30 (12) 0.22
Statin, n (%) 130 (35) 44 (34) 86 (35) 0.79
Clinical presentation
BMI, kg/m2 26.5 [24.0–29.4] 26.6 [24.4–26.7] 26.5 [23.7–29.4] 0.33
Systolic blood pressure, mmHg 140 [121–156] 138 [117–156] 142 [123–157] 0.15
Heart rate, beats/min 77 [64–90] 74 [60–87] 79 [66–91] 0.006
Serum creatinine, mmol/L 83 [72–97] 84 [73–98] 83 [71–95] 0.23
Time from symptom onset, min 253 [148–496] 282 [172–516] 245 [136–488] 0.14
Chest pain, n (%) 332 (88) 128 (98) 204 (83) ,0.001
ST-segment elevation, n (%) 69 (18) 67 (51) 2 (1) ,0.001
Coronary angiography, n (%) 165 (44) 128 (98) 37 (15) ,0.001
Abbreviations: CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting, PVD, peripheral
vascular disease; CVD, cerebrovascular disease; ACE, angiotensin converting enzyme; CCB, calcium channel blocker; BMI, body mass index.
doi:10.1371/journal.pone.0098626.t001
Clinical Criteria and Biomarkers in ACS
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e98626
Table 2. Final diagnoses.
Final diagnoses All patients Patients with cardiac events Patients free from cardiac events
(n =377) (n =131) (n =246)
Patients with ST-segment elevations
CAD 66 (96) 66 (50) 0
Cardiovascular death 1 (0.3) 1 (1) 0
Takotsubo cardiomyopathy 2 (0.6) 0 2 (1)
Patients without ST-segment elevations
CAD (NSTEMI, UA) 66 (18) 58 (44) 8 (3)
Arrhythmia 39 (10) 1 (1) 38 (15)
Musculoskeletal 55 (15) 0 55 (22)
Syncopal event 18 (5) 1 (1) 17 (7)
Hypertension 21 (6) 1 (1) 20 8)
Gastrointestinal 14 (4) 0 14 (6)
Panic attack 6 (1.6) 1 (1) 6 (2)
Pulmonary 5 (1.3) 0 5 (2)
Myocarditis 4 (1.1) 1 (1) 3 (1)
Congestive heart failure 2 (0.5) 0 2 (1)
Other 14 (3.7) 0 14 (6)
Unclear 64 (17) 0 64 (26)
Abbreviations: CAD, coronary artery disease; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina.
doi:10.1371/journal.pone.0098626.t002
Table 3. Biomarker levels in patients with and without cardiac events (CE).
Biomarker All patients Patients with cardiac events Patients free from cardiac events P value
(n =377) (n =131) (n=246)
Myocardial necrosis
CK 115 [76–183] U/L 139 [81–290] U/L 105 [71–155] U/L 0.001
CK-MB 18 [13–27] U/L 20 [14–42] U/L 17 [12–24] U/L ,0.001
H-FABP 2.4 [1.4–6.1] ng/mL 5.0 [1.9–18.7] ng/mL 2.0 [1.2–3.2] ng/mL ,0.001
Myoglobin 46 [32–77] mg/L 71 [42–209] mg/L 40 [31–58] mg/L ,0.001
c-cTnT 0.01 [0.01–0.01] mg/L 0.01 [0.01–0.19] mg/L 0.01 [0.01–0.01] mg/L ,0.001
hs-cTnT 11.6 [4.7–33.0] pg/mL 34.9 [16.3–235.3] pg/mL 7.4 [3.2–15.4] pg/mL ,0.001
Myocardial function
NT-proBNP 134 [48–674] ng/L 186 [51–940] ng/L 121 [45–406] ng/L 0.04
Inflammation
hs-CRP 2.4 [0.9–5.9] mg/L 3.0 [1.1–7.3] mg/L 2.2 [0.9–4.9] mg/L 0.02
IL-6 3.4 [1.9–7.5] ng/L 3.9 [1.9–6.4] ng/L 3.3 [1.9–8.1] ng/L 0.4
MPO 41 [26–68] ng/mL 57 [32–97] ng/mL 36 [24–104] ng/mL ,0.001
MRP 8/14 2.9 [2.0–4.5] mg/mL 3.6 [2.3–5.7] mg/mL 2.6 [1.8–3.7] mg/mL ,0.001
Atherosclerosis
PAPP-A 9 [7–13] mIU/L 11 [8–22] mIU/L 9 [7–11] mIU/L ,0.001
IGF-I 126 [98–157] mg/L 122 [95–150] mg/L 129 [100–163] mg/L 0.2
Coagulation
D-dimer 0.19 [0.19–0.39] mg/L 0.21 [0.19–0.45] mg/L 0.19 [0.19–0.37] mg/L 0.5
Fibrinogen 3.4 [2.8–4.3] g/L 3.4 [2.8–4.6] g/L 3.4 [2.7–4.2] g/L 0.3
Abbreviations: CK, creatine kinase; CK-MB, creatine kinase-myocardial band; H-FABP, heart-type fatty acid-binding protein; c-cTnT, conventional cardiac troponin T; hs-
cTnT, high-sensitive cardiac troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-CRP, high-sensitive C-reactive protein; Il-6, interleukin-6; MPO,
myeloperoxidase; MRP 8/14, myeloid-related protein 8/14; PAPP-A, pregnancy-associated protein A; IGF-1, insulin-like growth factor 1.
doi:10.1371/journal.pone.0098626.t003
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clinical TIMI risk scores, hs-cTnT significantly predicted CE
within 30 days (p,0.001 and p= 0.005), while it did not add to
risk prediction in patients with high (.3) clinical TIMI risk scores
(p = 0.35). To the contrary, MPO accurately predicted CE within
30 days in patients with high (.3) clinical TIMI risk scores
(p = 0.006), while ROC-analyses were not significant in patients
with low (#2) and intermediate ( = 3) clinical TIMI risk scores
(p = 0.23 and p= 0.35, respectively). ROC-analyses revealed no
significant AUC curves for MRP 8/14 independent of the clinical
TIMI risk group, and only significant values for low (#2) clinical
TIMI risk scores for c-cTnT (p= 0.013).
In Non-ST-elevation patients, multivariate decision tree analysis
incorporating clinical data and information of all 15 biomarkers
identified a model primarily based on clinical TIMI risk score
complemented by serum values of hs-cTnT as most predictive for
CE within 30 days (classification accuracy= 85.1%; figure 3). Age,
gender, and renal function did not affect classification tree
analyses. Using best cutoff-points for the clinical GRACE risk
score, no significant classification with regard to CE at 30 days was
possible in classification tree analysis (p = 0.37; figure 4).
Comparison of two risk models for the prediction of
cardiac events (CE) in Non-ST-elevation patients
In a binary logistic regression model to predict CE including all
biomarkers, the clinical TIMI and GRACE risk scores, as well as
age and gender, the clinical TIMI risk score, hs-TnT, and gender
were the only significant predictor variables. While both gender
(p = 0.03) and the clinical TIMI risk score (p = 0.002) remained
significant predictors, hs-cTnT was no longer significant (p = 0.30)
after bootstrapping.
To further elucidate the impact of hs-TnT on risk prediction
based on the clinical TIMI risk score, two risk models were
established, i.e. clinical TIMI risk score and gender alone (model I)
and combined with hs-TnT (model II). Female gender negatively
predicted CE in binary logistic regression analysis. The AUC was
0.84 (95% CI 0.78–0.89; p,0.001) for model I, and 0.87 (95% CI
0.83–0.92; p,0.001) for model II, respectively. We could neither
conclude equality (test of (AUC(model I)-AUC(model II)) = 0; diff
value = 0.067; p = 0.002) nor equivalence of the AUCs at the 5%
significance level (p = 0.087). An empirical non-inferiority test for
AUCs showed that model I is no worse than model II with a non-
inferiority bound of 5% (p,0.001), i.e. that the AUC for model I is
no less than the AUC for model II at the 5% significance level.
The addition of hs-TnT to base model I with an IDI of 0.054
indicates that the difference in average predicted risks between the
individuals with and without CE increased by 5.4% in model II
compared to model I. The performance of the two risk models is
illustrated by predictiveness curves (figure 5).
Discussion
This study assessed novel sensitive biomarkers along with
established clinical parameters on admission of patients with
suspected ACS, for the prediction of CE defined as a composite of
early coronary revascularization, myocardial infarction, and
cardiovascular death within 30 days. At variance with other
biomarker studies, in this analysis CE were prespecified to include
immediate revascularization therapy, since in the contemporary
setting of primary PCI for ACS, emergency room triage firstly
aims at identifying patients in need of PCI or CABG. Acute
coronary syndromes presenting as myocardial infarction may be
suspected or diagnosed by ECG already at admittance, and
diagnosis may be corroborated or not with biomarker testing.
Most likely, those patients will undergo cardiac catheterization
immediately. But in all patients with suspected ACS, identification
and therapy of a culprit lesion nowadays is paramount and
complementary to the clinical endpoints of myocardial infarction
and cardiovascular death within 30 days, which in turn may reflect
both success or failure of therapy, or a missed diagnosis in patients
not having undergone coronary angiography.
Importantly, this study showed that performance of single
biomarkers – notably of hs-cTnT and MPO – depend on the
clinical pretest probability of ACS, with hs-cTnT adding to the
sensitivity in patients with low and MPO improving the specificity
of patients with high clinical risk scores, respectively. Accordingly,
identification of those prone to CE was best based on clinical
criteria complemented by hs-cTnT based on decision tree analysis.
Interestingly, prediction of CE based on the clinical TIMI risk
score alone was not improved by adding hs-cTnT to the risk
prediction model. Although this study was originally designed also
to assess the diagnostic value of MRP 8/14 for early diagnosis of
ACS [16], in the current setting this marker of phagocyte
activation did not show sufficient discriminatory performance,
notwithstanding its significant elevation in ACS.
Scoring systems predicting the patients’ risk of ischemic events
and cardiovascular death have been established such as the TIMI
risk score for unstable angina/NSTEMI [23]. The TIMI risk score
is a simple, well-validated score for which prediction of cardiac
ischemic events and cardiovascular death has been shown in
patients with unstable angina or NSTEMI [26,27], and in patients
presenting with acute chest pain to the emergency department
[28]. The TIMI risk score offers clinical applications as it
categorizes patients with a wide, about 5- to 10-fold, range of
major adverse clinical events risk into different risk groups [23].
Indeed, patients with intermediate (score 3–4) and high-risk (score
5–7) scores, in particular those with prior history of PCI and
CABG, have been shown to benefit most from an early invasive
strategy as compared to low-risk patients. Therefore, a modified
TIMI risk score devoid of the biomarker component was used in
this study for comprehensive clinical risk assessment at patient
admission to the emergency department.
In this patient cohort, the clinical TIMI risk score outranged the
clinical GRACE risk score in predicting CE at 30 days. These
findings might at least in part be due to the different clinical
criteria incorporated in the two risk scores and the different
weighting of each criterion. While the GRACE risk score focuses
more on clinical parameters on admission such as heart rate and
systolic blood pressure, the TIMI risk score incorporates patient
history including risk factors for coronary artery disease, known
coronary artery disease, the use of antiplatelet therapy, and severe
episodes of angina [23,24]. Moreover, the endpoint definition of
this study varies from the ones used to validate these risk scoring
systems, and limited predictive value of the GRACE risk score has
previously been described [29]. However, this study was not
designed to allow a comparison between different risk scoring
systems, and further studies are needed to compare predictive
values of risk scores in different subsets of patients.
In ST-elevation patients, distinctive ECG patterns usually
determine an early invasive strategy with rare contraindications.
However, the heterogenous population of Non-ST-elevation
patients requires an appropriate patient selection for early
revascularization. Although the combination of clinical parameters
or risk scores, respectively with several conventional markers such
as c-cTnT and NT-proBNP have occasionally been suggested
[30,31], our findings show for the first time that integrating clinical
and novel cardiac biomarker data including continuous hs-cTnT
levels best predicted CE at 30 days in Non-ST-elevation patients.
Stand-alone, cardiac biomarkers including hs-cTnT were not
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better predictors of CE compared to clinical judgment using the
modified TIMI risk score. These findings further strengthen the
value of traditional clinical practice in assessing the probability
that the symptoms represent cardiac ischemia. Both safety issues
and limitations of health care resources demand the effective
targeting of therapy to those who are likely to benefit most in the
heterogeneous population of Non-ST-elevation patients.
Figure 2. Diagnostic performance of high-sensitive cardiac troponin T (hs-cTnT), myeloperoxidase (MPO), myeloid-related protein
8/14 (MRP 8/14), and conventional cardiac troponin T (c-cTnT) in relation to the clinical TIMI risk score of patients with suspected
ACS and no obvious ST-segment elevations at presentation (Non-ST-elevation patients). AUC indicates area under the curve. The clinical
TIMI risk score is the sum of 6 clinical factors without the biomarker variable of the 7 originally described risk predictors of the TIMI unstable angina/
Non-ST myocardial infarction risk score.
doi:10.1371/journal.pone.0098626.g002
Figure 3. Multivariate classification tree analysis of clinical and multiple biomarker information and the resulting algorithm for the
identification of those at risk of cardiac events (CE) within 30 days among patients presenting with suspected ACS and no apparent
ST-segment elevations (Non-ST-elevation patients). Hs-cTnT indicates high-sensitive cardiac troponin T (pg/mL), no-CE denotes patients free
from cardiac events (CE) within 30 days. The clinical TIMI score is the sum of 6 clinical factors without the biomarker variable of the 7 originally
described risk predictors of the TIMI unstable angina/Non-ST myocardial infarction risk score.
doi:10.1371/journal.pone.0098626.g003
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The use of the highly sensitive troponin assays has substantially
increased the number of chest pain patients tested troponin
positive [32]. This bears the potential of setting off an avalanche of
ischemia-related diagnostics. However, in patient with Non-ST-
elevation ACS, also low increases in troponin levels detected by
highly sensitive assays were reported to be associated with a higher
risk of cardiovascular death and myocardial infarction at 30 days
and at 1 year [33]. It is well known, that hs-cTnT is superior to
MPO for rapid and accurate diagnosis of acute myocardial
infarction among patients presenting with chest pain at the
emergency department [18,34,35]. Interestingly, MPO was not
predictive for CE in patients with clinical TIMI risk score #3,
whereas it was predictive in patients with higher risk scores. On
the contrary, with increasing clinical TIMI risk scores, c-cTnT and
hs-cTnT showed a gradual decline of the AUC for the prediction
of CE within 30 days. Hence, risk prediction of biomarkers such as
hs-cTnT and MPO clearly depends on the pretest probability.
Further studies are needed to understand the different risk
prediction profiles of hs-cTnT and MPO in low- and high-risk
patients with suspected ACS.
Interestingly, no improvement in risk prediction was observed
with the combination of the clinical TIMI risk score and hs-cTnT
with the pre-specified cut-off value of 13 pg/mL. Hence, in line
with previous data [33], the recommended and arbitrary defined
hs-cTnT decision limit seems to be less important for CE risk
prediction than continuous hs-cTnT levels including also low-level
increases. Furthermore, cut-off values of hs-cTnT may differ in
various patient populations as has been suggested for other
biomarkers such as NT-proBNP which shows dependency on age,
gender, and body mass index [36,37].
Figure 4. Multivariate classification tree analysis of clinical and multiple biomarker information and the resulting algorithm for the
identification of those at risk of cardiac events (CE) within 30 days among patients presenting with suspected ACS and no apparent
ST-segment elevations (Non-ST-elevation patients). No significant classification with regard to 30-day CE was possible using the clinical
GRACE risk score (Bonferroni-adjusted p-value= 0.368).
doi:10.1371/journal.pone.0098626.g004
Figure 5. Predictiveness curves illustrating the prognostic
performance of two different risk models in predicting cardiac
events (CE). Risk model I: clinical TIMI risk score and gender; Risk
model II: clinical TIMI risk score, gender, and hs-cTnT, respectively.
doi:10.1371/journal.pone.0098626.g005
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Limitations of this study are the single-centre design and the fact
that risk assessment was only performed at time of presentation to
the emergency department. However, this approach is in
accordance with the original design of the TIMI risk score for
prognostication at time of presentation [23]. The rather high rate
of patients presenting with ST-elevation myocardial infarction
observed might at least in part be due to the fact that the study was
performed at a tertiary referral center. However, the high rate of
coronary angiographies associated with this constellation allowed
for confirming or ruling out the diagnosis of coronary artery
disease based on current gold standard. Nevertheless, the fact that
decision making relied on c-cTnT measurements might have led
to an underestimation of true ACS needing validation. As binary
data whether events occurred or not were recorded in the study,
time-to-event analyses could not be included.
In conclusion, the combination of the patients’ clinical condition
as represented in the clinical TIMI risk score, and a biomarker
approach involving levels of continuous hs-cTnT, best predicted
30-day CE rate in Non-ST-elevation patients; thus, in this
heterogeneous patient population the traditional but nevertheless
sustainable clinical assessment remains fundamental for risk
stratification.
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